GT200600011A - Procedimientos para preparar eteres de pirazolo [3,4-d] pirimidina - Google Patents

Procedimientos para preparar eteres de pirazolo [3,4-d] pirimidina

Info

Publication number
GT200600011A
GT200600011A GT200600011A GT200600011A GT200600011A GT 200600011 A GT200600011 A GT 200600011A GT 200600011 A GT200600011 A GT 200600011A GT 200600011 A GT200600011 A GT 200600011A GT 200600011 A GT200600011 A GT 200600011A
Authority
GT
Guatemala
Prior art keywords
eteres
pirazolo
pyrimidine
procedures
prepare
Prior art date
Application number
GT200600011A
Other languages
English (en)
Inventor
Tawfik Gharbaoui
Dipanjan Sengupta
Edward A Lally
Naomi S Kato
Marlon Carlos
Natalie Rodriguez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600011A publication Critical patent/GT200600011A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA GENERAL I EN LA QUE R1,R2,R3,R5,R10,R13,R14,R15,R16,R17,M,N, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON MODULADORES DEL METABOLISMO DE LA GLUCOSA Y POR LO TANTO SON DE UTILIDAD EN EL TRATAMIENTO DE TRASTORNOS METABOLICOS TALES COMO LA DIABETES Y LA OBESIDAD.
GT200600011A 2005-01-13 2006-01-11 Procedimientos para preparar eteres de pirazolo [3,4-d] pirimidina GT200600011A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64371205P 2005-01-13 2005-01-13

Publications (1)

Publication Number Publication Date
GT200600011A true GT200600011A (es) 2006-08-10

Family

ID=36463499

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600011A GT200600011A (es) 2005-01-13 2006-01-11 Procedimientos para preparar eteres de pirazolo [3,4-d] pirimidina

Country Status (22)

Country Link
US (1) US7425630B2 (es)
EP (1) EP1838713A2 (es)
JP (1) JP2008526975A (es)
KR (1) KR20070114126A (es)
CN (1) CN101142216A (es)
AR (1) AR052557A1 (es)
AU (1) AU2006204940A1 (es)
BR (1) BRPI0606115A2 (es)
CA (1) CA2593345A1 (es)
CR (1) CR9224A (es)
DO (1) DOP2006000009A (es)
EA (1) EA013968B1 (es)
GT (1) GT200600011A (es)
HN (1) HN2006001493A (es)
IL (1) IL184365A0 (es)
MX (1) MX2007008381A (es)
NO (1) NO20074052L (es)
PA (1) PA8659701A1 (es)
PE (1) PE20061118A1 (es)
TW (1) TW200637865A (es)
WO (1) WO2006076455A2 (es)
ZA (1) ZA200705279B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AU2004257267B2 (en) * 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
AU2009270971A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
NZ590788A (en) 2008-09-08 2012-11-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of cns disorders
RS53167B (en) 2009-03-31 2014-06-30 Boehringer Ingelheim International Gmbh 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO [3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR APPLICATIONS AS A PDE9A MODULATOR
US20100285145A1 (en) * 2009-05-08 2010-11-11 Pfizer Inc Gpr 119 modulators
NZ596467A (en) * 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
GEP20156217B (en) 2010-08-12 2015-01-12 Boehringer Ingelheim Int 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
KR101871011B1 (ko) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
JP6567276B2 (ja) * 2014-05-13 2019-08-28 ソニーセミコンダクタソリューションズ株式会社 固体撮像素子、および電子機器
WO2016090380A1 (en) * 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
UA126268C2 (uk) 2015-01-06 2022-09-14 Арена Фармасьютікалз, Інк. СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub>
EA201890096A1 (ru) 2015-06-22 2018-08-31 Арена Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
JP2019122134A (ja) 2018-01-04 2019-07-22 Ntn株式会社 スイッチング電源の力率改善用ｐｗｍ制御装置
AU2022300325A1 (en) * 2021-06-23 2023-11-02 F. Hoffmann-La Roche Ag Process for the preparation of nlrp3 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3070304D1 (en) 1980-04-28 1985-04-25 Teijin Ltd Thiazolo(3,2-a)pyrimidine derivatives, process for preparing same, and drug containing same
EP0053678A1 (de) 1980-12-05 1982-06-16 BASF Aktiengesellschaft 5-Amino-1-phenyl-4-cyanpyrazole, diese enthaltende herbizide Mittel, Verfahren zu ihrer Herstellung und ihre Anwendung als Herbizide
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
JP4022271B2 (ja) * 1995-10-31 2007-12-12 富士フイルム株式会社 ピラゾリルアゾフエノール色素
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
EP1212327B8 (en) * 1999-09-17 2004-02-25 Abbott GmbH & Co. KG Pyrazolopyrimidines as therapeutic agents
DE10219435A1 (de) * 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
WO2004009602A1 (en) * 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
AU2004257267B2 (en) * 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PE20061118A1 (es) 2006-10-13
WO2006076455A8 (en) 2006-11-02
CA2593345A1 (en) 2006-07-20
ZA200705279B (en) 2008-11-26
CN101142216A (zh) 2008-03-12
DOP2006000009A (es) 2006-08-15
EA200701500A1 (ru) 2007-12-28
US7425630B2 (en) 2008-09-16
PA8659701A1 (es) 2006-09-08
BRPI0606115A2 (pt) 2009-06-02
WO2006076455A3 (en) 2006-12-07
JP2008526975A (ja) 2008-07-24
CR9224A (es) 2007-10-23
HN2006001493A (es) 2010-08-19
AR052557A1 (es) 2007-03-21
MX2007008381A (es) 2007-09-07
NO20074052L (no) 2007-09-12
IL184365A0 (en) 2007-10-31
TW200637865A (en) 2006-11-01
US20060154940A1 (en) 2006-07-13
AU2006204940A1 (en) 2006-07-20
KR20070114126A (ko) 2007-11-29
WO2006076455A2 (en) 2006-07-20
EA013968B1 (ru) 2010-08-30
EP1838713A2 (en) 2007-10-03

Similar Documents

Publication Publication Date Title
GT200600011A (es) Procedimientos para preparar eteres de pirazolo [3,4-d] pirimidina
CR20150131A (es) Derivados piridin-2-il-amino-1,2,4-tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
ATE528300T1 (de) Bizyklische verbindungen und ihre verwendung als antidiabetika
ECSP109921A (es) Sulfonamidas como moduladores de trpm8
CL2009000990A1 (es) Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras.
CR10948A (es) Compuestos triciclicos, composiciones y procedimientos
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
GT200500049A (es) Derivados de 1,6-naftiridina y 1,8-naftiridina y su uso para tratar la diabetes y trastornos relacionados
CO6270312A2 (es) Moduladores de gpr40 bifenilo-sustituidos
CL2009000135A1 (es) Compuestos derivados de 1,4-benzodiazepinas sustituidas, inhibidores de dipeptidilpeptidasa iv (dpp-iv); composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de enfermedades tales como diabetes tipo 2, cataratas, glaucoma, hipertrofia prostatica benigna, cancer, entre otras; compuestos intermediarios.
GT200800103A (es) 5-aril isoxazolinas para controlar plagas de invertebrados
GT200800258A (es) Compuestos de pirrolo-pirimidina y sus usos
CO6220948A2 (es) Derivados de ciclohexano espirociclico
MX2014014902A (es) Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
CL2011000249A1 (es) Compuestos derivados de 2-[1-sustituido-1h-pirazolo[3,4-d]pirimidin-4-il](tio, oxi o amino)-n-(heteroaril)-alcanoamidas; con actividada moduladora de glucoquinasa glk o gk; composicion farmaceutica que comprende y uso en el tratamiento de la diabetes tipo 2 y obesidad.
PA8584001A1 (es) Indol-3-carboxamidas como activadores de glucoquinasa (gk)
CL2007003733A1 (es) Compuestos derivados de indolin-2-ona, bencimidazol-2-ona y benzoxazol-2-ona, moduladores de serina palmitoiltransferasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 1 y 2, obesidad, aterosclerosis, hi
UY31803A (es) Compuesto cristalino
MX2009007436A (es) Derivados espirociclicos de acido tetronico.
DOP2006000087A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren